By LabMedica International staff writersPosted on 29 Feb 2024 Alzheimer’s disease, which traditionally requires costly scans or invasive spinal taps for diagnosis, is now closer to being more easily identified through innovative blood tests. This advancement is particularly crucial with the recent approval of disease-modifying treatments for Alzheimer’s. Now, the results of a study […]
Feb 28, 2024 | Jessica Kim Cohen NEW YORK – Results from blood-based biomarker tests correlated with the presence of beta-amyloid detected using established Alzheimer’s disease diagnostics, according to a study published Wednesday. PET scans and cerebrospinal fluid (CSF) analyses are highly accurate and established methods of identifying elevated levels of beta-amyloid, a hallmark of Alzheimer’s. However, these […]
The results of the Bio-Hermes study appear in Alzheimer’s & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over […]